RemeGen was cofounded in 2008 by Mr. Weidong Wang, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China, and Dr. Jianmin Fang, a Canadian-American scientist. Headquartered in the coastal city of Yantai, Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology and ophthalmic diseases.


Our mission is to discover, develop, and deliver innovative biologic drugs for major diseases in the autoimmune, oncology and ophthalmology spaces to fulfill the unmet medical needs of patients worldwide.


We aspire to be a leader within the global biopharmaceutical industry.

RemeGen’s Scientific Advisory Board comprises of five renowned professors and key opinion leaders in our areas of therapeutic development, including Dr. Gang Pei, Dr. Jianmin Fang, Dr. Ruyi He, Dr. Marsha A. Moses and Dr. Lorne Babiuk.

Dr. Gang Pei is a world-leading expert in the area of GPCR research, academician of the Chinese Academy of Sciences, former president of Tongji University and Shanghai Institute of Biological Sciences of Chinese Academy of Sciences. With more than 150 esearch publications in internationally renowned academic journals, Dr. Gang Pei has served in different academic research institutions in China and the world, including the Chinese Society of Cell Biology, the World Academy of Sciences, the Chinese Medicine Globalization Alliance. He is also the Editor-in-Chief of the prominent scientific journal, Cell Research.
Dr. Jianmin Fang has over 20 years of experience in biopharma research and development and more than 40 drug invention patents. Dr. Fang is the driving force in RemeGen’s innovation as the inventor of our core drug candidates including telitacicept (RC18), disitamab vedotin (RC48) and RC28. Prior to RemeGen, Dr. Fang already had a track record of successful drug discovery as the inventor of conbercept, the first wetAMD biologic drug commercialized in China. He is an exemplary pharmaceutical founder whose broad range of experience encompasses molecule discovery, drug research and development, target validation, CMC development to clinical studies. Dr. Fang is a Professor of Molecular Medicine at Tongji University in Shanghai, China and a member of the Scientific Advisory Board for the National Major Drug Innovation Program by the Ministry of Science and Technology and Ministry of Health of China where he advised on China’s drug innovation strategy. He received a Ph.D. in Biology from Dalhousie University in Nova Scotia, Canada and completed his postdoctoral fellowship at Harvard Medical School in Boston Children’s Hospital.
Dr. Ruyi He is authoritative expert in China’s drug clinical development of medicine in China and the global supervisory system. Dr. He previously served with the US Food and Drug Administration (FDA) for 17 years in numerous positions including Deputy Division Director. During his time at FDA, he was involved in FDA guidance development in multiple therapeutic areas. After his tenure at the FDA, Dr. He served as Chief Scientist at the CDE of the NMPA (National Medical Products Administration of China or the Chinese FDA). While at the CDE, Dr. He played a major role in implementing multiple policy reforms of the CDE and drug development in China. Dr. He has extensive experiences reviewing and approving INDs and NDAs in both China and US.
Dr. Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School, and the director of Vascular Biology Program at Boston Children's Hospital. Dr. Moses has had her research work published in prominent journals such as Science, The New England Journal of Medicine, Cell, PNAS, Nature Communications, and other journals. She also made prominent contributions in the understanding of the biochemical and molecular mechanisms that underlie the regulation of tumor development and progression. She has been named a pioneer in the field of biomarker medicine by the Journal of the National Cancer Institute, and elected as a member of the National Academy of Medicine (the Institute of Medicine) of the National Academies of the United States, the National Academy of Inventors, the American Institute for Molecular and Biological Engineering and the American Association for the Advancement of Science. She received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children's Hospital and MIT in the laboratory of Dr. Robert Langer.
Dr. Lorne Alan Babiuk is a Canadian scientist and a global authority in immunology, pathogenesis, virology, molecular virology, and vaccinology. He was the former Vice President of Research at the University of Alberta, and former director of the Vaccine and Infectious Disease Organization at the University of Saskatchewan. Dr. Babiuk has had over 500 scientific publications and has trained over one hundred doctors and postdoctoral researchers. He is an Officer of the Order of Canada and a member of the Royal Society of Canada. He has won the Saskatchewan Medal of Merit, the Medal of Honor for Canadian Officials, and the Gairdner Foundation Whiteman Award among other awards. Dr. Babiuk obtained a doctorate degree from the University of British Columbia in Canada and was awarded Honorary Doctor of Science at Colorado State University in the United States, University of Guelph in Canada and University of Saskatchewan in Canada.
TwitterFacebook微博

Company Wechat

© All Right Reserved .  ICP:鲁ICP备11031710号-1